Thanks for the link JM.
Make no mistake, in the right hands this product is a global multi-million dollar success.
It has no peers, the market leader HAS been made obsolete. Not "will make it obsolete", has already made it obsolete.
Why would you even bother buying a product with the same active ingredients that just doesn't work as good as its upgraded version.
It has no peer, it has no rival. It must go global, but in the hands of someone who will take Novartis on head on. Not position it on the back shelves and hope for the best.
Multi-multi millions.
It would make a significant dent into the oral diclofenac market as well.
Opioids are a long road ahead, diclofenac is right in front of us.
Voveran TPM vs voltaren, page-7
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(16.7%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $3.226K | 1.116M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 92468918 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 76402411 | 25 |
View Market Depth
| Last trade - 12.50pm 06/09/2024 (20 minute delay) ? |
| AVE (ASX) Chart |